Lung cancer ranks no.1 among all malignant tumors in terms of incidence and mortality rates[1,2]It is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), accounting for about 87% and 13% of all cases, respectively. Lung squamous cell carcinoma (LSCC) (30–35%), adenocarcinoma (LAD) (50–60%), and large cell carcinoma (5–10%) are the most common histologic subtypes of NSCLC [3,4]There are very limited effective treatment strategies for LSCC. Before 2015, targeted agents have not yet been developed for LSCC and chemotherapy continues to be the standard treatment[5,6]Fortunately, nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor, has been approved this year for the treatment of LSCC in the second-line settingHowever, the overall response ratio of nivolumab is just about 15%. Thus, novel treatment strategies are still urgently needed for patients with LSCC.
1] Yalman, D., Neoadjuvant radiotherapy/chemoradiotherapy in locally advanced non-small cell lung cancer. Balkan Med J, 2015. 32(1): p. 1-7.
2] Uzel, E.K. and U. Abacioglu, Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? Balkan Med J, 2015. 32(1): p. 8-16.
3] Whithaus, K., et al., Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med, 2012. 136(2): p. 155-62.
4] Chen, G. and X.H. Yi, [Pathology and genetics of disease and tumours of the lung, pleura in China]. Zhonghua Bing Li Xue Za Zhi, 2005. 34(8): p. 490-3.
5] Scagliotti, G.V., et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008. 26(21): p. 3543-51.
6] Tiseo, M., et al., FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev, 2015.
7] Ang, Y.L., H.L. Tan, and R.A. Soo, Best practice in the treatment of advanced squamous cell lung cancer. Ther Adv Respir Dis, 2015.